U.S. markets close in 2 hours 27 minutes
  • S&P 500

    +26.93 (+0.83%)
  • Dow 30

    +153.67 (+0.57%)
  • Nasdaq

    +142.58 (+1.34%)
  • Russell 2000

    +16.12 (+1.11%)
  • Crude Oil

    -0.14 (-0.35%)
  • Gold

    -10.40 (-0.55%)
  • Silver

    -0.09 (-0.39%)

    -0.0049 (-0.42%)
  • 10-Yr Bond

    -0.0050 (-0.75%)

    -0.0044 (-0.34%)

    +0.2230 (+0.21%)

    -89.91 (-0.84%)
  • CMC Crypto 200

    +9.81 (+4.50%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.80 (+0.51%)

Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

RADNOR, Pa., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the upcoming presentation of EEG data from its Phase 2 study at the American Clinical Neurophysiology Society (ACNS) 2020 Annual Meeting in New Orleans, Louisiana on February 7, 2020. The data from the study demonstrate a rapid, dose-dependent and sustained reduction of seizure burden in patients with status epilepticus (SE) treated with ganaxolone. In addition, an independent central review of EEG seizure data provided objective diagnostic confirmation in these patients of a clear dose effect, with the target dose level providing sustained reductions in seizure burden (greater than 80%) throughout the entire analysis window.

Presentation details:








Intravenous Ganaxolone Achieves Rapid and Dose-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory Status Epilepticus” 



A. M. Husain, et al.



# 793677. Poster Number F53



Friday, February 7



7:30 pm to 9:00 pm Central Time

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever pivotal studies in children with CDKL5 deficiency disorder and PCDH19-related epilepsy. Based on results from a recent Phase 2 study in refractory SE and from biomarker analysis research, the Company intends to initiate later this year a Phase 3 study in SE and a Phase 2 study in Tuberous Sclerosis Complex (TSC), respectively. For more information visit www.marinuspharma.com. Please follow us on Twitter: @MarinusPharma.

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical study testing schedule and milestones, the ability to complete enrollment in our clinical studies, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, the timing of the clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, the attainment of clinical study results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Lisa M. Caperelli
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.